Portrait of bald doctor smiling with stethoscope and lab coat

Expand your options for OAB patients with NURO Percutaneous Tibial Neuromodulation (PTNM)

Learn more

NURO delivers PTNM for bladder control

Percutaneous Tibial Neuromodulation (PTNM) restores bladder function* without the side effects of medication or the potential need to self-catheterize.1 While the NURO device was not used in the study, since it delivers equivalent stimulation as the device used, a user can expect similar performance.

PTNM, delivered by the Medtronic NURO™ system, is a safe and effective office-based treatment for overactive bladder (OAB). Delivered with an external neurostimulator, PTNM expands your options for OAB patients.2

The NURO device self-administers therapy for 30 minutes while the patient remains comfortably seated. Stimulation levels are adjustable, even in the middle of a session.
The NURO system uses the NURO device along with a single-use therapy session kit. Once you have your device, simply order therapy session kits from Medtronic Connect as needed.

How to deliver a NURO session

Get an overview of this simple procedure and therapy session.

View video

Clinical outcomes

See clinical data showing the safety and effectiveness of PTNM.

View data

Customer support

Get help if you have questions or need technical assistance.

Contact support

*

Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

The most common side effects are temporary and include mild pain or skin inflammation at or near the stimulation site.


1

Peters, K. M., S. A. Macdiarmid, et al. (2009). "Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial." J Urol 182(3): 1055-1061.

2

Kobashi K, Khandwala S, MacDiarmid S, et al. A Prospective Study to Evaluate Efficacy with the NURO Percutaneous Tibial Neuromodulation System in Drug Naïve Patients with overactive bladder syndrome (OAB). Presented at the American Urological Association 2018 Annual Meeting. Journal of Urology. 2018;199(4) Supplement, Page e987.